EA201990393A1 - COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 USED FOR TREATING VARIOUS DISEASES AND DISORDERS - Google Patents

COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 USED FOR TREATING VARIOUS DISEASES AND DISORDERS

Info

Publication number
EA201990393A1
EA201990393A1 EA201990393A EA201990393A EA201990393A1 EA 201990393 A1 EA201990393 A1 EA 201990393A1 EA 201990393 A EA201990393 A EA 201990393A EA 201990393 A EA201990393 A EA 201990393A EA 201990393 A1 EA201990393 A1 EA 201990393A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
disorders
methods
various diseases
treating various
Prior art date
Application number
EA201990393A
Other languages
Russian (ru)
Inventor
У. Джейсон Каммингс
Грегори А. Демопулос
Томас Дадлер
Ханс-Вильхельм Швебле
Ларри У. Хьелкер
Кристи Л. Вуд
Мунехиса Ябуки
Original Assignee
Омерос Корпорейшн
Юниверсити Оф Лестер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Омерос Корпорейшн, Юниверсити Оф Лестер filed Critical Омерос Корпорейшн
Priority claimed from PCT/US2017/044714 external-priority patent/WO2018026722A1/en
Publication of EA201990393A1 publication Critical patent/EA201990393A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к MASP-3-ингибирующим антителам и композициям, содержащим указанные антитела, для их применения в целях ингибирования побочных эффектов MASP-3-зависимой активации комплемента.The present invention relates to MASP-3 inhibitory antibodies and compositions containing these antibodies, for their use in order to inhibit the side effects of MASP-3-dependent complement activation.

EA201990393A 2017-03-29 2017-07-31 COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 USED FOR TREATING VARIOUS DISEASES AND DISORDERS EA201990393A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478336P 2017-03-29 2017-03-29
PCT/US2017/044714 WO2018026722A1 (en) 2016-08-01 2017-07-31 Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders

Publications (1)

Publication Number Publication Date
EA201990393A1 true EA201990393A1 (en) 2019-07-31

Family

ID=67399625

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990393A EA201990393A1 (en) 2017-03-29 2017-07-31 COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 USED FOR TREATING VARIOUS DISEASES AND DISORDERS

Country Status (1)

Country Link
EA (1) EA201990393A1 (en)

Similar Documents

Publication Publication Date Title
JOP20220245A1 (en) Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
EA201990912A1 (en) ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS
EA201891910A1 (en) PAD4 HETEROARYLINARY INHIBITORS
EA201990043A1 (en) ANTIBACTERIAL CONNECTIONS
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA201792047A1 (en) NEW CONNECTIONS
EA201691134A1 (en) NEW GLUTAMINASE INHIBITORS
EA201991720A1 (en) ANTIBODIES TO ALPHA-SINUCLEIN AND THEIR APPLICATIONS
EA201891251A1 (en) PAD4 BICYCLIC INHIBITORS
EA201891539A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201990400A1 (en) COMPOUNDS AND COMPOSITIONS AND THEIR APPLICATION
EA202091731A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
EA201692313A1 (en) Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase
EA202091865A1 (en) COMPOSITIONS AND METHODS FOR REDUCING THE EXPRESSION OF TAU
EA201892225A1 (en) ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION
EA201891347A1 (en) Aza-benzimidazole inhibitors PAD4
EA201692474A1 (en) DERIVATIVES 1- (CYCLOPENT-2-EN-1-IL) -3- (2-HYDROXY-3- (ARYLSULFONIL) PHENYL) URECHEN AS CXCR2 Inhibitors
EA202090414A1 (en) COMPOUNDS AND THEIR APPLICATION
EA202091655A1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF RETINAL DISORDERS
EA201791937A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES
EA201990508A1 (en) ACTIVITY INHIBITION Olig2
EA202191058A1 (en) ANTIBODIES AGAINST MUCIN-16 AND METHODS OF THEIR APPLICATION
EA202092446A1 (en) THIAZOL- OR THIADIAZOL-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS Vps34 INHIBITORS